Amlodipine/celecoxib

Drug Profile

Amlodipine/celecoxib

Alternative Names: Celecoxib/amlodipine; KIT 302

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Kitov Pharmaceuticals
  • Class Antihypertensives; Antirheumatics; Dihydropyridines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Cyclo-oxygenase 2 inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension; Pain

Most Recent Events

  • 07 Dec 2016 Amlodipine/celecoxib (KIT-302) successfully completes 6 months stability testing required for the submission of a NDA
  • 01 Nov 2016 Kitov Pharmaceuticals initiates enrolment in a phase III trial for Hypertension in the United Kingdom (NCT02979197)
  • 27 Sep 2016 Pharmacokinetics data from a bioequivalence study released by Kitov Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top